×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Press Release

View printer-friendly version
Amgen Appoints Francois de Carbonnel to the Company's Board of Directors
THOUSAND OAKS, Calif., Oct 03, 2008 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN) announced today that its Board of Directors has appointed Francois de Carbonnel to the Company's Board. Mr. de Carbonnel, 61, is a consultant and corporate financial advisor. He is also chairman of the board of Thomson S.A. (Euronext Paris:18453; NYSE:TMS), an international multimedia corporation. He is also a member of the boards of Pages Jaunes S.A., a French public company, Quilvest S.A., a public Luxembourg company, Ecofin Global Utilities Hedge Fund Ltd. and Ecofin North America Utilities Hedge Fund Ltd., both Irish public companies. His appointment brings the number of Amgen Board members to 12. Mr. de Carbonnel will serve as a member of the Audit and Governance and Nominating Committees of the Board.

Until the end of 2006, Mr. de Carbonnel was a consultant/senior advisor to Citigroup's Corporate and Investment Bank and to Citigroup Venture Capital, based in London. Previously, he was a managing director and member of the Operating Committee (New York and London) of Citigroup's Corporate and Investment Bank, which he joined in 1999. He held different senior positions globally and in Europe. Prior to Citigroup he was chairman and chief executive officer of MIDIAL S.A. based in Paris.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

SOURCE: Amgen

Amgen, Thousand Oaks
David Polk, 805-447-4613 (media)
Arvind Sood, 805-447-1060 (investors)